SCHEMBL12438047

SCHEMBL12438047

Cc1cc(C)cc(Nc2nc(C)cc(Nc3cc(C4CC4)[nH]n3)n2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11346083 0.86 IGF1R (1.00) IGF1R
SCHEMBL16247096 0.83 IGF1R (0.73) IGF1R
SCHEMBL16247021 0.82 IGF1R (0.71) IGF1R
SCHEMBL12430952 0.80 IGF1R (0.67) IGF1R
SCHEMBL4959505 0.80 IGF1R (0.66) IGF1R
SCHEMBL11344820 0.80 IGF1R (0.66) IGF1R
SCHEMBL2321718 0.78 IGF1R (0.68) IGF1R
SCHEMBL13054530 0.78 IGF1R (0.63) IGF1R
SCHEMBL27239823 0.78 IGF1R (0.63) IGF1R
SCHEMBL18297004 0.76 IGF1R (0.61) IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1841760-B1 PYRIMIDINE DERIVATIVES AS KINASE MODULATORS AND METHOD OF USE EXELIXIS INC (US) 2011-08-10 — — EP disclosed
WO-2008127594-A2 COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS, INC. (US) 2008-10-23 — — WO disclosed
WO-2008076415-A1 METHODS OF USING MEK INHIBITORS EXELIXIS, INC. (US) 2008-06-26 — — WO disclosed
Send feedback